NCT06248931CompletedPhase 3
Valproate Versus Topiramate in Migraine
Valproate Versus Topiramate in Migraine, a Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 15 Jul 2024
Brief summary (registry, in English)
Investigators aim to compare the effect of valproate versus topiramate in migraine by assessing the reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (actual)
- First submitted
- 31 Jan 2024
- Start date
- 1 May 2022
- Primary completion date
- 10 Jun 2024
- Lead sponsor
- Kafrelsheikh University
- Diseases
- Migraine
- NCT number
- NCT06248931
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 600
- From 1 May 2022 to the primary completion date, 10 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with valvular and ischemic heart diseases, bradycardia or heart blocks, congestive heart failure patients who received prophylactic treatment for migraine, patients with any contraindications to drugs used in the study Patients with topiramate or valproate contraindications.
Other illness
- Patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors.
- Patients with major systemic diseases such as malignancy, collagen, liver, and renal diseases.
Lab values
- Patients with cardiovascular diseases like hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/Hg on at least three different occasions, diabetes (fasting plasma glucose level \>126 mg/dl and/or a casual plasma glucose \>200 mg/dl and/or HbA1C more than 6.5.
Who the study is looking for
- Naive migraine patients, according to the International Classification of Headache Disorders 3rd edition, aged 18-75 years,
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kafr-Elsheikh University Hospital Coordinator of this site? Confirm its status | Kafr ash Shaykh | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.